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Ovarian reserve can be diminished following treatment for breast cancer. This study evaluated biochemical and biophysical
parameters of ovarian reserve in these patients. Biochemical and biophysical tests of ovarian reserve were performed simultaneously
in young (age 22–42 years), regularly menstruating women with breast cancer (n¼22) and age-matched controls (n¼24). All tests
were performed before (baseline) and after transient ovarian stimulation in the early follicular phase. Patients were recruited both
before and after completion of chemotherapy, with some patients being followed up prospectively. Serum samples were analysed for
follicle-stimulating hormone (FSH), luteinising hormone (LH), oestradiol (E2), inhibins A and B, and antimullerian hormone (AMH).
Biophysical (ultrasound) tests included ovarian volume, antral follicle count (AFC), ovarian stromal blood flow and uterine dimensions.
Significant differences were revealed (when compared with the controls) for basal FSH (11.3271.48 vs 6.6270.42mIUml
 1,
Po0.001), basal AMH (0.9570.34 vs 7.8971.62ngml
 1, Po0.001) and basal inhibin B (19.2474.56 vs 83.61713.45pgml
 1,
Po0.001). Following transient ovarian stimulation, there were significant differences in the increment change (D) for inhibin B
(3.0272.3 vs 96.82716.38pgml
 1, Po0.001) and E2 (107.8723.95 vs 283.2740.34pgml
 1, Po0.01). AFC was the only
biophysical parameter that was significantly different between patients and the controls (7.8070.85 vs 16.7771.11, Po0.001). Basal
and stimulated biochemical (serum AMH, FSH, inhibin B and E2) and biophysical (AFC) tests may be potential markers of ovarian
reserve in young women with breast cancer.
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As the incidence of breast cancer has progressively increased,
survival rates have simultaneously improved, owing to improve-
ments in early detection and adjuvant chemotherapy (Jatoi and
Miller, 2003). Young women with breast cancer are considered
high risk (Goldhirsch et al, 2001), and are likely to receive
chemotherapy, as the magnitude of benefit seems to be enhanced
(Gradishar, 2003). As a result, these women are likely to suffer
ovarian damage from chemotherapy, which can have a profound
effect on their quality of life.
At present, it is impossible to predict the lifespan of the
chemotherapeutically damaged ovary. Ovarian reserve testing has
become established in the fertility setting where it is used to
predict outcome in assisted reproduction (Bukulmez and Arici,
2004). These tests have the potential to estimate the reproductive
lifespan of the ovaries, which would allow an accurate estimation
of fertility status and the risk of premature ovarian failure.
There is a need for such tests to be validated in patients with
breast cancer, so that the information needs of these patients can
be met, and appropriate measures taken to improve their fecundity
and overall quality of life.
The aim of this study was to evaluate ovarian function in young
women treated by multi-agent, cyclophosphamide-based che-
motherapy for breast cancer by using clinical, biochemical and
biophysical parameters. This was based on the hypothesis that
cytotoxic drugs used to treat premenopausal patients with breast
cancer can cause ovarian damage resulting in diminished ovarian
reserve.
PATIENTS AND METHODS
In this pilot study, pre-menopausal recipients of chemotherapy for
breast cancer were analysed in two groups – a longitudinal arm
(group 1) and a cross-sectional arm (group 2). As all patients were
recruited from a single centre, the chemotherapy regimens
employed were standardised. There were two predominant
regimens, both cyclophosphamide-based. The first was E-CMF,
which consisted of four cycles of epirubicin (E), followed by
four cycles of Cyclophosphamide (C), methotrexate (M) and
5-fluorouracil (F). The second was FEC, which consisted of six
cycles of 5-fluorouracil, epirubicin and cyclophosphamide.
Some patients received taxanes (docetaxel or paclitaxel), usually
as part of a therapeutic trial (TANGO). The cumulative dosages
received by patients in the longitudinal analysis are displayed in
Table 1.
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receiving chemotherapy. The same patients were then followed up
longitudinally by performing further testing immediately following
chemotherapy. In group 2, patients were tested for ovarian reserve
before chemotherapy (some patients were also part of the
longitudinal study) and after chemotherapy (once regular men-
strual cycles had resumed). Patients with oestrogen-sensitive
cancer were recruited provided they had not taken tamoxifen or
gonadotrophin releasing hormone analogue (GnRHa) (goserelin or
leuprolin) for at least the preceding 12 weeks.
Controls were age matched, had no medical illness, had proven
fertility (defined by virtue of having at least one childbirth
previously) and had a normal menstrual history. Those on oral
contraception were asked to discontinue it and use alternative
(barrier) contraception for at least 8 weeks before testing.
Informed consent was obtained from all participants. This study
received ethical approval from the Joint UCL/UCLH Ethics
Committee.
Biochemical tests
Biochemical tests included follicle-stimulating hormone (FSH),
luteinising hormone (LH), oestradiol (E2), inhibins A and B,
activin A and antimu ¨llerian hormone (AMH). Blood samples
(15ml) were obtained from all subjects during the early follicular
phase of the menstrual cycle (day 2–5). Four-timed samples were
performed, 15min apart (to account for the pulsatile variation of
FSH release). Following the last-timed sample, the gonadotrophin
analogue stimulation test (G-test) was commenced (Ranieri et al,
1998). This involved administering a GnRHa – Buserelin 1mg
subcutaneously. This route was chosen to ensure compliance in
preference to intranasal administration, which would have
involved four divided doses over 24h. Administration of the
G-test was intended to produce a transient ovarian stimulation.
This response is quantified after performing a single repeat blood
sample approximately 24h later.
Serum was separated and stored at  201C before hormone
measurements. Assaying each of the four samples and determining
an average value then determined mean serum concentrations for
FSH, LH and E2. For the inhibins and AMH, pooled samples were
obtained from the four-timed samples before assaying (obtained
by mixing equivalent volumes from each timed sample before
freezing).
Assays Follicle-stimulating hormone and LH: all samples were
assayed in duplicate using a commercial Coat a count solid phase
Immunoradiometric assay (DPC, Gwynedd, UK). The sensitivity of
the assay is 0.06mIUml
 1 and the intra- and interassay variation
was o7%.
Oestradiol: All samples were assayed in duplicate using a
commercial ELISA kit (IBL Immunobiological Laboratories,
Hamburg, Germany) according to the manufacturer’s protocol.
The sensitivity of the assay was 4.6pgml
 1 and the intra- and
interassay variation was o6%.
Inhibin A: Serum concentrations of dimeric inhibin A were
measured in duplicate 50ml aliquots as described previously
(Muttukrishna et al, 1994). The sensitivity of the assay was
2pgml
 1 and the intra- and interassay variations were o6%.
Inhibin B: All samples were assayed in duplicate using a
commercial ELISA kit (Oxford bio innovations-DSL, Oxford, UK)
according to the manufacturer’s protocol. The sensitivity of the
assay is 10pgml
 1. The intra- and interassay variations were
o10%.
Table 1 Clinical data of patients in longitudinal group
PT.
Age/
years Parity
Cycle/
days
BMI
(kg/m
2) Histological diagnosis
Chemotherapy
regime
Cumulative
dose
1 39 0+0 5/32 25 23mm grade 3 ductal ca; ER/PR moderately pos,
HER2 3+0/7 nodes pos
FEC 6F ¼5760mg
E¼576mg
C¼5760mg
2 35 0+0 7/30 23 50mm grade 2/3 ductal ca; ER weakly pos, 2/18 nodes pos FEC 6F ¼6600mg
E¼660mg
C¼6600mg
3 32 0+0 4/26 24 18mm grade 3 ductal ca, weakly ER pos 1/14 nodes pos EC 4
Paclitaxel 4
Gemcitabine 4
E¼688mg
C¼4400mg
P¼1392mg
G¼19152mg
4 35 0+0 5/30 30 25mm grade 2 ductal ca; ER/PR neg; HER2 3 pos; 0/8 nodes pos FEC 6F ¼6480mg
E¼648mg
C¼6480mg
5 33 0+0 5/30 21 grade 3 ductal ca, ER/PR neg, HER2 1pos FEC 6F ¼5810mg
E¼596mg
C¼5810mg
6 41 1+1 5/28 26 42mm high grade DCIS with 2 invasive foci grade 2;
ER/PR neg; 2/12 nodes pos
EC 4 paclitaxelx4 E¼702mg
C¼4700mg
P¼1368mg herceptin
7 31 0+1 3/34 20 Grade 3 Invasive ductal ca; ER/PR neg; HER2 3pos EC 4 paclitaxelx4 E¼564mg
C¼3740mg
P¼1074mg herceptin
8 38 0+0 6/28 25 Grade 2 ductal carcinoma, ERpos, HER2neg E 4
CMF 4
E¼8284mg
C¼9920mg
M¼640mg
F¼9600mg
BMI, body mass index; C, cyclophosphamide; E, epirubicin; ER, oestrogen receptor status; F, fluorouracil; G, gemcitabine; HER2, HER2 receptor status; M, methotrexate; neg,
negative; P, paclitaxel; pos, positive; PR, progesterone receptor status. The patients in this group comprised the longitudinal arm of the study, with all patients having ovarian
reserve tests performed before receiving chemotherapy. Cycle length is depicted first by menstruation length followed by cycle length in days. As per the study protocol, all
patients in this group had ovarian reserve tests performed between cycle days 2–5. Relevant details of diagnosis and chemotherapy regimen (including cumulative dosages) are
shown.
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‘total’ activin A as described previously (Muttukrishna et al, 1996).
The detection limit of this assay for human recombinant activin A
(Genentech INC, San Francisco, CA, USA) was 50pgml
 1. Intra-
and interassay variations were 8.5 and 9.8%, respectively.
Antimullerian hormone: All samples were assayed in duplicate
using a commercial assay kit according to the manufacturer’s
sensitised assay protocol (Immunotech, Marseille, France). The
sensitivity of the assay was 0.098ngml
 1. The intra- and interassay
variations were o15% using an in-house quality control pool.
Biophysical tests
Ultrasound examination was performed on the same day that
blood samples were taken (before ovarian stimulation). Inter-
observer variability was minimised by having all ultrasound scans
performed by a single investigator (AP). Additional support for
performing scans was provided specifically by another investigator
(BP) if required. An Acuson 128 XP4 (Acuson USA) with a 2.5–
4mHz-vector probe (transabdominal) and a 5–7.5mHz EC-7
(transvaginal) probe were used to perform the scans.
Ultrasound parameters
Antral follicle count Round- or oval-shaped echo-free structures
from 2 to 10mm within the ovaries were considered to be follicles.
Total antral follicle count (AFC) was the sum of antral follicles
measured from both ovaries.
Ovarian volume Ovarian volume was calculated for each ovary
using the prolate ellipsoid formula:
Ovarian volume¼D1 D2 D3 p/6, where D1, D2 and D3 are
maximal perpendicular diameters of the ovary.
Mean pulsatility index and mean peak systolic velocity Ovarian
stromal blood flow velocity waveforms were obtained by placing
the Doppler gate over the ovarian stroma, which had the highest
achievable signals, ensuring that no arteries near the surface of the
ovary were measured. Peak systolic velocity and pulsatility indices
from both ovaries were then combined to provide the mean
pulsatility index and mean peak systolic velocity, respectively.
Uterus Uterine cross-sectional area (cm
2) and endometrial
thickness (mm) were calculated by examining the uterus in the
sagittal plane.
Statistical analyses
A normality test was carried out to assess the distribution of data.
Most variables in the cross-sectional data analysis had a gaussian
distribution. As such, unpaired Student’s t-tests were carried out to
compare biochemical and biophysical parameters between patients
and controls. One-way analysis of variance used to compare
baseline parameters only. A P-value o0.05 was considered
statistically significant. When a significant difference was found,
a post hoc test (Bonferroni’s multiple comparisons) was used to
compare differences between individual groups. For non-gaussian
distribution, the Mann–Whitney test was employed.
Data in the longitudinal group, which had a normal distribution,
were analysed using the paired t-test. Non-parametric variables
were analysed using the Wilcoxon-signed rank test.
Statistical analyses were performed using GraphPad Prism
version 3.00 for Windows (GraphPad Software, San Diego CA,
USA) and Statistical Package for Social Sciences (SPSS Inc.,
Chicago, IL, USA).
RESULTS
All tests performed were well tolerated, with no adverse effects
reported. Results are presented as mean values along with the
standard error of the mean (s.e.m.).
Cross-sectional data
Clinical parameters There was no statistically significant differ-
ence (P40. 05) in age among all the three groups. The mean age
for patients in the pre-chemotherapy group was 35.271.5, for
patients in the post-chemotherapy group 36.770.6 and in the
controls 34.570.9. Similarly, there was no statistically significant
difference in body mass index (BMI) (kgm
 2) among the three
groups. The mean BMI for patients in the pre-chemotherapy group
was 24.2770.84, for patients in the post-chemotherapy group
24.5970.53 and in the controls 26.0471.02 (Figure 1A).
Biochemical parameters All biochemical tests included basal (b)
estimates as well as stimulated and delta (stimulated – baseline, D)
results following administration of the G-test. There were no
significant differences in biochemical parameters between patients
in the pre-chemotherapy arm and the controls.
In the post-chemotherapy arm, there were significant differences
when compared to the controls for basal FSH (11.3271.48 vs
6.6270.42mIUml
 1, Po0.001), basal AMH (0.9570.34 vs
7.8971.62ngml
 1, Po0.001) and basal inhibin B (19.2474.56 vs
83.61713.45pgml
 1, Po0.001). One-way ANOVA revealed sig-
nificant differences in the mean values for all three groups (pre-
chemotherapy, post-chemotherapy and controls) for basal FSH,
basal AMH and basal inhibin B (Po0.001). Basal E2 was
significantly lower in the control group compared with patients
in the pre-chemotherapy group (144.7726.13 vs 252.07
49.1pgml
 1). Following administration of the G-test, there were
significant differences between patients in the post-chemotherapy
arm and the controls for stimulated FSH (but not A ¨ FSH) (22.697
1.77 vs 17.571.37mIUml
 1, Po0.05); stimulated and delta E2
(208.9737.5 vs 427.9755.87pgml
 1 (stimulated), Po0.01;
107.8723.9 vs 283.2740.34pgml
 1 (delta), Po 0.01) and finally
stimulated and delta inhibin B (22.576.04 vs 180.4722.8pgml
 1
(stimulated), Po0.001; 3.0272.3 vs 96.82716.38pgml
 1 (delta),
Po0.001). One-way ANOVA revealed significant differences over-
all among the three groups (pre-chemotherapy, post-chemother-
apy and controls) for stimulated FSH (Po0.01), stimulated and
delta E2 (Po0.01) and stimulated and delta inhibin B (Po0.001)
(Figure 1B and C).
Biophysical parameters There were no significant differences in
biophysical parameters between patients in the pre-chemotherapy
arm and the controls.
In the post-chemotherapy arm, total (and mean) AFC was the
only biophysical parameter that displayed a significant difference
between patients in the post-chemotherapy arm and the controls
(TAFC 7.870.9 vs 17.171.2, Po0.001; MAFC 4.470.5 vs 8.570.6,
Po0.001). One-way ANOVA showed a highly significant difference
in the mean TAFC among the three groups (Po0.0001).
(Figure 1D).
Longitudinal data
In this data set, patients were tested during the early follicular
phase of the menstrual cycle preceding chemotherapy and
immediately following completion of chemotherapy. It is impor-
tant to note that patients tested immediately post-chemotherapy
were universally amenorrhoeic, and as such were not offered the
G-test. All parameters were tested for normality and most were
found to have a gaussian distribution. Significant findings in this
group are displayed in Figure 2.
Ovarian reserve predictors in young women with breast cancer
K Lutchman Singh et al
1810
British Journal of Cancer (2007) 96(12), 1808–1816 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sA Age
Control Control Pre-chemo Pre-chemo Post-chemo
Control Pre-chemo Post-chemo
Control Post-chemo
Control Pre-chemo Post-chemo
Post-chemo
0
10
20
30
40
34.46±0.87
(n=24)
35.20±1.47
(n=15)
36.68±0.57
(n=22)
A
g
e
/
y
e
a
r
s
NS
Body mass index
0
5
10
15
20
25
30
35
NS
B
M
I
 
k
g
/
m
2
B Basal fsh***
0.0
2.5
5.0
7.5
10.0
12.5
15.0
P<0.01
p<0.05
p<0.05
p<0.05
NS
F
S
H
 
m
I
U
/
m
l
Basal E2 **
0
50
100
150
200
250
300
350
NS
E
2
 
p
g
/
m
l
∆ FSH
Pre-chemo Control Post-chemo Pre-chemo
0.0
2.5
5.0
7.5
10.0
12.5
15.0
NS
NS
NS
∆
F
S
H
 
m
I
U
/
m
l
∆ ∆ E2 **
0
50
100
150
200
250
300
350
400
P<0.01
NS
P<0.05
∆
 
E
2
 
p
g
/
m
l
26.04±1.02
(n=24)
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(n=24)
6.09±0.49
(n=14)
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(n=21)
283.2±40.34
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10.88±1.33
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Figure 1 (A) Clinical data of study group. This figure illustrates the mean age and BMI, respectively, of patients and controls in the cross-sectional analysis.
BMI, body mass index; NS, no statistically significant difference. (B–D) Biochemical and biophysical parameters (cross-sectional data). Mean basal hormone
parameters are displayed as well as delta (D) values, which are obtained by subtracting hormone levels obtained following stimulation from the baseline. (B)
Follicle-stimulating hormone and E2,( C) AMH and inhibin B, (D) total (and mean) AFC and OV. Significant differences are highlighted with an asterisk (*) as
follows: *Po0.05; **Po0.01; ***Po0.001; NS, no statistically significant difference.
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Figure 1 Continued.
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patients’ pre-chemotherapy compared with post-chemotherapy
levels (7.971.4 vs 46.7710.8mIUml
 1, Po0.01). In addition,
basal AMH and basal inhibin B levels were much higher in patients
tested pre-chemotherapy compared with post-chemotherapy,
but these results were not statistically significant (4.471.1 vs
0.0770.02, P40.05 (AMH, ngml
 1); 62.5729.8 vs 6.070.6,
P40.05 (inhibin B, pgml
 1)).
Biophysical parameters Both total and mean AFCs were sig-
nificantly higher in patients tested pre-chemotherapy compared
with post-chemotherapy (15.072.7 vs 5.170.7, Po0.01 (TAFC);
7.571.3 vs 2.770.3, Po0.01 (MAFC). There were no other
statistically significant differences between the pre-chemotherapy
and post-chemotherapy biophysical markers, including total and
mean ovarian volume (OV) (11.170.9 vs 8.471.6, P40.05 (TOV,
ml); 5.670.5 vs 4.370.7, P40.05 (MOV, ml).
Correlations
Correlation statistics were performed using SPSS comparing each
of the ovarian reserve markers within each of the three groups
studied: controls, pre-chemotherapy and post-chemotherapy
patients, respectively. Bivariate analysis was performed using
Pearson’s correlation coefficients. Significant correlations were
flagged at the 0.01 level (two-tailed) or the 0.05 level (two-tailed).
Antimu ¨llerian hormone as a basal marker correlated with DE2 in
patients and the controls (r¼0.759, Po0.001 and r¼0.518,
Po0.05, respectively), as well as basal inhibin B (r¼0.842,
Po0.001). Furthermore, AMH was the only parameter (in addition
to bFSH) to correlate with chronological age in patients only
(r¼0.78, Po0.05).
D Inhibin B correlated best with biophysical markers of ovarian
reserve. In controls, inhibin B correlated positively with TAFC
and MAFC (r¼0.494, Po0.05; r¼0.509, Po0.05), whereas D
E2 correlated positively with TAFC in the pre-chemotherapy group,
but not the controls (r¼0.670, Po0.05).
Overall, basal markers, which appeared to correlate the most
with other markers, were AMH and inhibin B. Post-stimulation,
however, E2 and inhibin B were the only markers to correlate with
AFC. No correlations with OV were identified.
DISCUSSION
The results of this study show that biochemical and biophysical
tests may be used to accurately estimate ovarian reserve in
premenopausal recipients of chemotherapy for breast cancer.
This study confirms the observation of a recent paper where the
new ovarian reserve tests, such as inhibin B, AMH and AFC, were
investigated in breast cancer patients before and after treatment
(Anderson et al, 2006). However, our study is the first in which
dynamic ovarian reserve testing (G-test) has been evaluated in
breast cancer patients. In an IVF setting, basal ovarian markers can
be normal yet these patients do not respond to stimulation. Hence,
dynamic tests are used in the assisted reproductive technology
setting as they give a better indication of the ovarian response to
stimulation. We believe the G-test can add to the discriminatory
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Figure 2 Biochemical and biophysical parameters (longitudinal data). Mean basal levels of FSH, E2, AMH, inhibin B, total AFC and total OV are displayed in
the same patients tested in the early follicular phase pre-chemotherapy as well as immediately following completion of chemotherapy. Significant differences
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scapacity provided by basal markers alone, as the underlying
pathophysiology of chemotherapy-mediated gonadotoxicity is in
fact dynamic.
In the recently published study, AMH concentration in
particular was found to be useful as an early indicator of ovarian
ageing, including the assessment of chemotherapy-induced
ovarian follicle loss (Anderson et al, 2006). Contrary to this study
where the patients were 28–52 years of age, our study cohort
comprised a significantly younger patient cohort (mean age of
patients was 41.3 in the chemotherapy arm of the Anderson study,
compared with 35.2 and 36.7 in the pre-chemotherapy and post-
chemotherapy arms of our study), and included an age-matched
control group with proven fertility. This was in keeping with our
objective, which was to evaluate ORT in young women with breast
cancer. It is this group where validation of ORT could potentially
lead to adequate counselling and treatment with regards fertility
preservation, at a time when therapeutic intervention is still
feasible.
Previous studies in breast cancer were focused mainly on the
incidence of amenorrhoea and premature menopause (Bines et al,
1996; Goodwin et al, 1999). Other investigators assessed the
endocrine consequences of chemotherapy in patients with breast
cancer, but the analysis was limited to gonadotrophin and steroid
alterations (Padmanabhan et al, 1987; Dowsett and Richner, 1991;
Mehta et al, 1992). These studies were performed long before the
concept of ovarian reserve was realised. The importance of these
alterations were accurately surmised as being detrimental to
fertility, but the limitations of these studies prevented meaningful
application in clinical practice (Hensley and Reichman, 1998).
Prospective studies are limited and have been performed in women
and men with haematological malignancy (Chatterjee et al, 1994;
Wallace et al, 1997).
Our data suggest that ovarian reserve was intact before
chemotherapy in a breast cancer cohort, implying that multi-
agent chemotherapy was the main factor that led to diminished
ovarian reserve. Alkylating agents such as cyclophosphamide,
which are non cell-cycle specific, are more toxic to the ovaries than
cell-cycle-specific agents, such as methotrexate and fluorouracil. It
is unclear, however, what effect multi-agent chemotherapy has on
ovarian reserve, especially, given the fact that newer agents are
continually being developed (Awada et al, 2003). All the
biochemical and biophysical markers with the exception of basal
oestradiol (bE2) levels provided evidence that ovarian reserve was
intact before chemotherapy.
The G-test is a dynamic ovarian reserve test. It was chosen in
this study, as it provided an ovarian response, which was less
potent than the HMG test, an important factor to consider in
patients with breast cancer. Although bE2 levels were significantly
higher in patients (pre-chemotherapy) compared with the controls,
there was no significant difference between stimulated and delta E2
levels. This may be explained by the fact that bE2 levels correlate
more with the underlying disease, as it has been shown that high
plasma E2 concentrations have been linked to breast cancer
development regardless of menopausal status (Clamp et al, 2002).
Oestradiol increase in response to the G-test, however, probably
correlates better with ovarian reserve, which would explain the
lack of a significant difference in patients compared with the
controls in addition to the other markers of ovarian reserve.
Perhaps, the main factor involved in assessing these patients
appropriately is the fact that the pathophysiological process is
dynamic, with both acute and cumulative effects. As such, efforts
to grade the extent of ovarian damage, and indeed ovarian
recovery by clinical, biochemical and biophysical parameters are
limited by the dynamic processes involved (Chatterjee and
Kottaridis, 2002). Furthermore, extrapolation of data from one
cancer cohort to another is inappropriate due to differences in
disease, type of chemotherapy and the demographics of the
population studied.
In the fertility setting, the most important aspect of diminished
ovarian reserve and the associated decline in reproductive
potential is that its onset is highly variable (Scott and Hofmann,
1995). To the best of our knowledge, it appears that no single
marker can be clinically useful in assessing ovarian reserve,
leading to the evaluation of multiple markers (Lutchman Singh
et al, 2005).
Our study group comprised regularly cycling patients and
controls. Although all patients had undergone a variable period of
amenorrhoea following chemotherapy, clinical characteristics
alone (patient age, BMI and parity) were not found to be
discriminatory once cyclical activity resumed. This is in keeping
with the generally accepted notion that clinical characteristics are
not reliable estimates of reproductive age.
Biochemical parameters, which appeared to discriminate
between patients and the controls in the cross-sectional data set,
were serum FSH, E2, inhibin B and AMH. The data relating to the
use of FSH in estimating ovarian reserve in breast cancer are
limited. Although widely used in a reproductive medicine setting,
its main limitations arise from a lack of reproducibility (Sharara
et al, 1998). The pulsatile nature of FSH secretion is believed to be
one of the factors responsible for this variation. To minimise this
possibility, we took four (4)-timed samples, 15min apart and used
a mean value as a ‘true’ representative figure. Basal FSH levels were
significantly different across the three groups (controls, pre-
chemotherapy and post-chemotherapy patients, P¼0.0006). Fol-
lowing the G-test, stimulated FSH levels were also significantly
different (P¼0.01). However, DFSH levels did not confer any
discriminatory capacity. Follicle-stimulating hormone is an
indirect marker of ovarian reserve and depends on the presence
of an intact hypothalamic-pituitary-ovarian (HPO) axis. Admin-
istration of the G-test causes a temporary increase in pituitary
secretion of FSH and LH, to which the ovaries respond by releasing
E2. It is the amount of E2 released (D), which correlates with
ovarian reserve, not DFSH, which is in keeping with the results.
Basal oestradiol levels were significantly higher in the pre-
chemotherapy group compared with the controls. This may have a
role in the pathophysiological process of breast cancer as
described earlier. No significant difference existed between the
controls and the post-chemotherapy group. In fact, higher levels of
bE2 were seen in the pre-chemotherapy group as opposed to the
post-chemotherapy, which one would not expect, as higher levels
of E2 are associated with diminished ovarian reserve. Both
stimulated and delta E2 levels were significantly different, however,
being much lower in the post-chemotherapy group compared with
the pre-chemotherapy group and the controls, respectively. This
supports the notion that the G-test confers discriminatory
capacity.
Basal, stimulated and D inhibin B levels were all significantly
different between patients and the controls. Although inhibin B is
mainly secreted by pre-antral follicles (Klein et al, 1996), inhibin A
is produced primarily during the late follicular phase by mature
follicles and the corpus luteum (Roberts et al, 1993). This would
explain why the former is a more reliable marker of ovarian
reserve, as our results confirm. The added discriminatory capacity
as provided by the G-test for inhibin B and E2 is consistent with the
theory that the pathophysiological processes taking place within
the ovary are in fact dynamic – thus necessitating a dynamic form
of assessment.
Antimullerian hormone is considered a direct marker of ovarian
reserve, as it is produced by FSH-sensitive early antral follicles. In
this way, it may be a more sensitive predictor of ovarian reserve
than other markers, such as AFC and inhibin B, which detect more
mature primordial follicles. Antimullerian hormone has a rela-
tively stable expression over the menstrual cycle (Cook et al, 2000;
La Marca et al, 2006). This would explain why serum AMH levels
were mostly unchanged in our study following the G-test, a
phenomenon detected in other studies (van Rooij et al, 2002;
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sPastor et al, 2005). Our results confirm that basal AMH levels were
dramatically reduced in the post-chemotherapy group compared
with both the controls and the pre-chemotherapy group.
With regard to biophysical parameters, our data suggest that
AFC is most useful. Although studies in cancer are limited, AFC
and OV have been found to be useful in assessing ovarian reserve
in childhood survivors of cancer (Larsen et al, 2003a,b) and
patients undergoing bone marrow transplantation (Chatterjee
et al, 1994). Our results did not show a significant difference in
OV between patients and the controls, although it was approaching
significance (P¼0.06).
Longitudinal data analysis revealed that the parameters, which
were discriminatory between these two groups, were FSH, E2 and
AFC. It can be deduced that the multi-agent chemotherapy
received by these patients suppressed ovarian function resulting
in a hypoestrogenic state, with a corresponding high FSH and
amenorrhoea. Reduced AFC reflects a reduction in the number of
antral follicles and is consistent with our observation in the cross-
sectional population (post-chemotherapy cycling women). Ovarian
volume, as was the case in the cross-sectional data, was not
significantly different between both groups. This may be a
reflection of the fact that the induced hypoestrogenic state was
temporary. It can be argued that in terms of reproductive ageing, a
reduction in OV is a relatively late event that comes about after a
protracted period of diminished ovarian reserve. It is plausible that
despite these patients being amenorrhoeic, the unchanged OVs
implied that resumption of ovarian function, albeit at a level lower
than the pre-chemotherapy state, was likely to occur. In fact, all
patients in the post-chemotherapy arm of the cross-sectional
analysis had resumed normal menses, indicating that the effects of
the multi-agent chemotherapy received were at least partially
reversible.
In summary, this study confirms the use of biochemical and
biophysical parameters of ovarian reserve in a breast cancer
cohort. The methodology was robust and included elaborate
methods of testing – all of which appeared to be well tolerated. The
cohort was disease standardised and received cyclophosphamide-
based chemotherapy. Biochemical markers, which appeared to be
discriminatory, included FSH, AMH, inhibin B and E2 in response
to the G-test. The only clearly discriminatory biophysical marker
was the AFC. There was good correlation between AFC and other
markers of ovarian reserve. These results taken together support
the hypothesis that ovarian reserve is reduced in young, regularly
cycling women following treatment with chemotherapeutic agents
for breast cancer. The data also add to the understanding of the
pathophysiological processes involved.
These findings have major implications for breast cancer
survivors, for whom reproductive issues are a major concern
(Partridge et al, 2004). Furthermore, the potential exists for
ovarian reserve testing to be applied in patients with different
types of cancer. To achieve this, a large sample size should be
followed up longitudinally to determine the potential therapeutic
role of ovarian reserve testing in this cohort.
In conclusion, this study confirms that ovarian reserve can be
assessed in breast cancer patients using AFC, inhibin B and AMH
to inform patients on their prospects of fertility treatment post
chemotherapy.
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